pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
the cabinet

Drugs

8,127 products tracked

★ save view↓export CSV
phase
allMarketedPhase 3Phase 2Phase 1Preclinical
sort
catalystsrecentname
therapeutic area
allOncology1831Infectious Disease718Cardiology425Pulmonology396Immunology371Ophthalmology368Dermatology300Women's Health131
viewlistcards
  • REVUFORJ
    REVUFORJ (REVUMENIB CITRATE)
    1 INDICATIONS AND USAGE REVUFORJ is a menin inhibitor ind…$SNDX Syndax Pharmaceuticals Inc
  • Phase 1
    REX-8756
    Asthma Recludix Pharma Inc
  • REZDIFFRA
    REZDIFFRA (RESMETIROM)
    1 INDICATIONS AND USAGE REZDIFFRA is indicated in conjunc…$MDGL MADRIGAL PHARMACEUTICALS, INC.
  • REZENOPY
    REZENOPY (NALOXONE HYDROCHLORIDE)
← prev
page 148 of 271
next →
Pain89
Neurology1
1 INDICATIONS AND USAGE REZENOPY nasal spray is indicated…
$SCNX Scienture Holdings, Inc.
  • REZUROCK
    REZUROCK (BELUMOSUDIL MESYLATE)
    no indication Kadmon Pharmaceuticals LLC
  • REZZAYO
    REZZAYO (REZAFUNGIN ACETATE)
    no indication Mundipharma EDO GmbH
  • Preclinical
    RFT-1041
    Alzheimer's Disease RAFT Pharmaceuticals LLC
  • Preclinical
    RFT-1124
    Post-Operative Pain RAFT Pharmaceuticals LLC
  • Phase 2
    RG-6351
    Diabetic Macular Edema Genentech Inc
  • Phase 1
    RG-6538
    Refractory Multiple Myeloma F. Hoffmann-La Roche Ltd
  • Phase 1
    RG-6540
    Diffuse Large B-Cell Lymphoma F. Hoffmann-La Roche Ltd
  • Phase 2
    RG-6596
    Human Epidermal Growth Factor Receptor 2 Positive Breast… F. Hoffmann-La Roche Ltd
  • Phase 2
    RG-6794
    Human Epidermal Growth Factor Receptor 2 Negative Breast… Genentech Inc
  • Phase 1
    RGDCRAdcox-2F
    Pancreatic Cancer University of Minnesota
  • Phase 2
    RGI-2001
    Graft Versus Host Disease (GVHD) REGiMMUNE Ltd
  • Preclinical
    RGN-6024
    Glioblastoma Multiforme (GBM) Reglagene Holding Inc
  • Phase 1
    RGT-61159
    Adenoid Cystic Carcinoma (ACC) Rgenta Therapeutics Inc
  • Phase 1
    RGVax
    Human Papillomavirus (HPV) Associated Cancer Pathovax LLC
  • RHAPSIDO
    RHAPSIDO (REMIBRUTINIB)
    1 INDICATIONS AND USAGE RHAPSIDO ® is indicated for the t…$NVS NOVARTIS AG
  • Phase 1
    RHB-204
    (clarithromycin + clofazimine + rifabutin)
    Crohn's Disease (Regional Enteritis)$RDHL RedHill Biopharma Ltd.
  • Preclinical
    RHLAM-111
    Laminin-Deficient Congenital Muscular Dystrophy (LAMA2 MD… Sarcomatrix Therapeutics Corp
  • pre_registration
    RILPIVIRINE HYDROCHLORIDE
    RILPIVIRINE HYDROCHLORIDE
    Human Immunodeficiency Virus (HIV) Infections (AIDS)$JNJ JOHNSON & JOHNSON
  • Phase 1
    RIM-730
    Coronavirus Disease 2019 (COVID-19) RNAimmune Inc
  • RINGERS
    RINGERS (SODIUM CHLORIDE, CALCIUM CHLORIDE, POTASSIUM CHLORIDE,)
    no indication BAXTER HLTHCARE
  • RINVOQ
    RINVOQ (UPADACITINIB)
    1 INDICATIONS AND USAGE RINVOQ/RINVOQ LQ is a Janus kinas…$ABBV AbbVie Inc.
  • RINVOQ LQ
    RINVOQ LQ (UPADACITINIB)
    inflammatory bowel disease$ABBV AbbVie Inc.
  • Phase 2
    RIV3 + rC19
    Coronavirus Disease 2019 (COVID-19)$SNY Sanofi
  • Phase 1
    RIVASTIGMINE
    RIVASTIGMINE
    Dementia Associated With Alzheimer's Disease Lachesis Biosciences Ltd
  • RIVASTIGMINE TARTRATE
    RIVASTIGMINE TARTRATE
    no indication AUROBINDO PHARMA
  • Preclinical
    RK-33
    Triple-Negative Breast Cancer (TNBC) Natsar Pharmaceuticals Inc